Published in J Control Release on July 06, 2001
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 2.28
The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta (2011) 1.64
MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J (2009) 1.37
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther (2013) 1.08
Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res (2004) 1.06
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity. Cancer Gene Ther (2012) 0.98
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther (2013) 0.95
Radionuclide carriers for targeting of cancer. Int J Nanomedicine (2008) 0.94
MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development. Cancer Res (2014) 0.93
Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta (2009) 0.92
Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des Devel Ther (2014) 0.92
MicroRNAs, stem cells and cancer stem cells. World J Stem Cells (2012) 0.91
Monodisperse double-walled microspheres loaded with chitosan-p53 nanoparticles and doxorubicin for combined gene therapy and chemotherapy. J Control Release (2012) 0.88
MiRNAs and LincRNAs: Could they be considered as biomarkers in colorectal cancer? Int J Mol Sci (2012) 0.87
Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res (2011) 0.84
Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials (2013) 0.81
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett (2015) 0.80
Delivery of calf thymus DNA to tumor by folate receptor targeted cationic liposomes. Biomaterials (2011) 0.79
Radiation improves gene delivery by a novel transferrin-lipoplex nanoparticle selectively in cancer cells. Cancer Gene Ther (2008) 0.79
Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system. Mol Ther (2013) 0.79
[The use of p53 as a tool for human cancer therapy]. Mol Biol (Mosk) (2008) 0.75
Folate receptor-mediated targeted polymeric gadolinium complexes for magnetic resonance imaging in pulmonary tumor xenografts. Exp Ther Med (2012) 0.75
WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma. Exp Ther Med (2016) 0.75
Barriers to Liposomal Gene Delivery: from Application Site to the Target. Iran J Pharm Res (2016) 0.75
Mechanism of activation of a human oncogene. Nature (1982) 12.09
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (1991) 7.49
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 5.08
Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus. J Virol (1980) 4.91
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48
Characterization of a human colon/lung carcinoma oncogene. Nature (1983) 3.26
Functional organization of the Harvey murine sarcoma virus genome. J Virol (1980) 2.46
Transformation by cloned Harvey murine sarcoma virus DNA: efficiency increased by long terminal repeat DNA. Science (1980) 2.05
Dispersion of the ras family of transforming genes to four different chromosomes in man. Nature (1983) 1.82
Interferon-directed inhibition of chronic murine leukemia virus production in cell cultures: lack of effect on intracellular viral markers. J Virol (1975) 1.49
Amplification and rearrangement of onc genes in mammalian species. Nature (1982) 1.48
Molecular cloning of the Harvey sarcoma virus circular DNA intermediates. II. Further structural analyses. J Virol (1980) 1.45
Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther (1999) 1.45
Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry (1991) 1.39
Prediction of the three-dimensional structure of the transforming region of the EJ/T24 human bladder oncogene product and its normal cellular homologue. Proc Natl Acad Sci U S A (1983) 1.37
Interferon inhibits mouse leukaemia virus release: an electron microscope study. J Gen Virol (1977) 1.31
Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun (1984) 1.29
Physical, morphological, and biochemical alterations in the membrane of AKR mouse cells after interferon treatment. Proc Natl Acad Sci U S A (1978) 1.23
Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med (2001) 1.21
Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol (1993) 1.19
The effect of interferon on de novo infection of Moloney murine leukemia virus. Cell (1977) 1.16
Infrequent RAS oncogene mutations in human prostate cancer. Prostate (1992) 1.10
Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther (1997) 1.06
Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res (1993) 1.05
Oncogenes in radioresistant, noncancerous skin fibroblasts from a cancer-prone family. Science (1987) 0.97
A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther (2004) 0.96
Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. Radiat Res (1993) 0.96
A large glycoprotein of Moloney leukemia virus derived from interferon-treated cells. Biochem Biophys Res Commun (1977) 0.95
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther (2013) 0.95
Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs (2000) 0.94
The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. Carcinogenesis (1992) 0.93
The inhibitory effect of interferon on a temperature-sensitive mutant of Moloney murine leukemia virus. Virology (1977) 0.93
Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene (1993) 0.93
3'-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells. Bioconjug Chem (2000) 0.92
The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res (1991) 0.92
Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun (1997) 0.91
Patterns of wave break during ventricular fibrillation in isolated swine right ventricle. Am J Physiol Heart Circ Physiol (2001) 0.91
Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. Genes Chromosomes Cancer (1992) 0.90
Development of transformed phenotype induced by a human ras oncogene is inhibited by interferon. Biochem Biophys Res Commun (1985) 0.90
Non-viral gene delivery for p53. Curr Opin Mol Ther (2000) 0.89
Characterization of interferon messenger RNA synthesis in Namalva cells. J Biol Chem (1980) 0.89
Modulation of ras expression by anti-sense, nonionic deoxyoligonucleotide analogs. Oncogene Res (1989) 0.88
Oncogene- transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat Res (1993) 0.87
p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene (1997) 0.86
Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther (2001) 0.84
Pathogenicity of retroviruses containing either the normal human c-Ha-ras1 gene or its mutated form derived from the bladder carcinoma EJ/T24 cell line. J Exp Pathol (1985) 0.84
Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer. Br J Cancer (1991) 0.84
Association of interferon-gamma induced growth inhibition and modulation of epidermal growth factor receptor gene expression in squamous cell carcinoma cell lines. J Biol Regul Homeost Agents (1989) 0.83
Persistence of the viral genome in interferon-treated cells infected with oncogneic or nononcogenic viruses. J Infect Dis (1976) 0.82
Structural abnormalities in murine leukemia viruses produced by interferon-treated cells. Biochem Biophys Res Commun (1979) 0.82
Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther (2001) 0.82
Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J Urol (1993) 0.82
Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today (2000) 0.81
Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis. Cancer Res (1993) 0.81
Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg (1990) 0.81
Physical characterization methods for iron oxide contrast agents encapsulated within a targeted liposome-based delivery system. Nanotechnology (2008) 0.80
raf involvement in the simultaneous genetic transfer of the radioresistant and transforming phenotypes. Int J Radiat Biol (1989) 0.80
Sequence specific inhibition of in vitro translation of mutated or normal ras p21. J Exp Pathol (1989) 0.80
Assignment of RAS proto-oncogenes in Chinese hamsters: implications for mammalian gene linkage conservation and neoplasia. Cytogenet Cell Genet (1986) 0.78
Dynamics of differentiation in human epidermoid squamous carcinoma cells (A431) with continuous, long-term gamma-IFN treatment. In Vitro Cell Dev Biol (1991) 0.78
Interferon-induced modulation of human ras oncogene expression. Prog Clin Biol Res (1985) 0.78
Biological and morphological characteristics of phenotypic revertants appearing in interferon-treated mouse cells transformed by a human oncogene. J Exp Pathol (1985) 0.78
Membrane alterations following interferon treatment. Adv Exp Med Biol (1978) 0.78
Interferon and glycoprotein hormones. Tex Rep Biol Med (1977) 0.78
Mechanisms of antioncogenic activity of interferon. Prog Clin Biol Res (1985) 0.77
Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy. Arch Otolaryngol Head Neck Surg (1997) 0.77
A fragment of the human c-Ki-ras1 pseudogene (HGM9 gene symbol KRAS1P), localized to 6p12-p11, detects 3 allele, RFLP. Nucleic Acids Res (1988) 0.75
A study of the bronchial provocation test with methacholine in patients with active pulmonary tuberculosis. Korean J Intern Med (1989) 0.75
[The effect of thermal power plant on microbial ecology and environmental quality]. J Microbiol Immunol Infect (1999) 0.75
Inhibition of Ras p21 synthesis by antisense undecamers with uniform and specifically arranged phosphorothioate linkages. Anticancer Drugs (2000) 0.75
Harmonic analysis of homogeneous networks. IEEE Trans Neural Netw (1995) 0.75